US 12,528,855 B2Granted

KRAS variant mRNA molecules

AssigneeCureVac AG

InventorsAmit Aggarwal, Katja Fiedler, Ulrike Gnad-Vogt, Regina Heidenreich, Mythili Koneru, Gregory D. Plowman

Life of this patent

Estimating the term…

Abstract

The present invention provides an mRNA molecule encoding at least one KRAS variant peptide. Further, the invention provides a pharmaceutical composition and kit comprising the mRNA molecule. The mRNA molecule, pharmaceutical composition and kit are useful for treating cancer.

Claims19

Dependent claims

An mRNA molecule comprising an mRNA sequence encoding an amino acid sequence comprising a CTLA4 signal peptide, a KRAS variant peptide, PADRE-derived T helper epitope sequence, and a CTLA4 transmembrane domain.

Dependencies are inferred from the claim text.

Facts

Application: 17/413,654Filed 6 Dec 2019 · us provisional application
Priority: 14 Dec 2018
Published: US 2022/0340641 A127 Oct 2022
Granted: 20 Jan 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification24 codes

C07K 14/70539
Immunoglobulin superfamily: mHC-molecules, e.g. HLA-molecules
C07K 14/82
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: translation products from oncogenes
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/1272
Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers: comprising non-phosphatidyl surfactants as…

Family

Application62/779,858Us provisional application · filed 14 Dec 2018
Application62/788,285Us provisional application · filed 4 Jan 2019
US 2022/0340641 A1Pre-grant publication · published 27 Oct 2022
US 12,528,855 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results